Related Experiment Video
Updated: Dec 27, 2025
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.3K
Screening study for genetic polymorphisms affecting pharmacokinetics of talniflumate
Li Hua Jin1, Bo-Hyung Kim1, Ji Hyun Lee1
1Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, Seoul 02447, Korea.
Translational and Clinical Pharmacology
|February 26, 2020
Summary
Genetic factors significantly influence how the body processes talniflumate, affecting its absorption and peak concentration. This research identifies specific gene variants that could lead to personalized talniflumate therapies for inflammatory disorders.
Area of Science:
- Pharmacogenomics
- Drug Metabolism and Transport
- Inflammatory Disease Therapeutics
Background:
- Talniflumate, a niflumic acid derivative, possesses potent analgesic and anti-inflammatory properties, commonly prescribed for conditions like rheumatoid arthritis.
- Understanding the pharmacokinetic variability of talniflumate is crucial for optimizing its therapeutic efficacy and safety.
- Genetic polymorphisms are known to influence drug metabolism and transport, potentially impacting drug pharmacokinetics.
Purpose of the Study:
- To identify genetic factors influencing the pharmacokinetic parameters of talniflumate in a Korean population.
- To explore the association between single nucleotide polymorphisms (SNPs) in drug-metabolizing enzymes and transporters and talniflumate pharmacokinetics.
- To provide a basis for the development of personalized talniflumate therapy.
Main Methods:
- Whole genome SNP analysis was performed on 23 male Korean volunteers using the Illumina Human610Quad v1.0 DNA Analysis BeadChip.
- Pharmacokinetic parameters (Cmax, Tmax, AUCinf) of talniflumate were analyzed using linear regression against genotyping data.
- Specific SNPs in genes including ABCA4, CYP2C9, CYP24A1, and SLC1A6 were investigated for their association with talniflumate PK parameters.
Main Results:
- A large number of significant SNPs (P < 0.0001) were associated with Cmax (1498), Tmax (65), and AUCinf (1491).
- Two SNPs, rs11165069 (ABCA4) and rs17847036 (CYP2C9), were significantly associated with talniflumate Cmax.
- Significant associations were found between SNPs rs3787555 (CYP24A1) and rs2275034 (ABCA4) for Tmax, and rs11165069 (ABCA4) and rs12461006 (SLC1A6) for AUCinf.
Conclusions:
- Genetic variations significantly affect the pharmacokinetic parameters of talniflumate, including its absorption and peak plasma concentration.
- Identified SNPs in ABCA4, CYP2C9, CYP24A1, and SLC1A6 are potential genetic markers influencing talniflumate disposition.
- These findings support the potential for tailoring talniflumate treatment based on an individual's genetic profile for improved therapeutic outcomes.
Keywords:
Drug metabolizing enzymePharmacogenomicsPharmacokineticsSingle nucleotide polymorphismTalniflumateMore Related Videos
Related Concept Videos
01:27Nonlinear Pharmacokinetics: Role of Transporters
227
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
227
01:29Therapeutic Drug Monitoring: Affecting Factors
136
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
136
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
130
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
130
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
550
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
550
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
194
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
194
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
167
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
167